Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adoptive T Cell Therapy in Recurrent Ovarian Cancer
NCT04072263Phase 2Unknown
- Sponsor
- Leiden University Medical Center
- Start
- Aug 2018
- Primary completion
- Aug 2021
- Modality
- Monoclonal Antibodies, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of autologous tumor-infiltrating lymphocytes in Epithelial Ovarian Cancer (EOC), sponsored by Leiden University Medical Center. Status: unknown.
02
Drugs
autologous tumor-infiltrating lymphocytes
03
Conditions
Epithelial Ovarian Cancer (EOC)
Beyond the preview
Go deeper on NCT04072263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04072263.